ADRB2 and pachyonychia congenita: These patients, undergoing surgery and receiving non-selective BBs, including propranolol, showed fewer intratumoral S-100+ structures (a reduced nerve density), decreased staining for BDNF, a trend toward a lower perineural invasion/nerve and better survival, as compared with patients not receiving BBs, or receiving selective B1Bs, thus supporting a correlation between ADRB2 blockade and clinical outcome in PC [72].